Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Indiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 86 | 4,542 | 35% |
| 2020 | 66 | 3,807 | 39% |
| 2021 | 73 | 4,080 | 44% |
| 2022 | 75 | 3,957 | 47% |
| 2023 | 77 | 4,158 | 51% |
| 2024 | 79 | 4,130 | 53% |
| 2025 from claims | – | 3,969 3,643–4,200 | 54% |
| 2026 forecast | – | 4,042 3,557–4,665 | 55% |
| 2027 forecast | – | 4,102 3,506–4,888 | 55% |
| 2028 forecast | – | 4,161 3,472–5,095 | 56% |
| 2029 forecast | – | 4,220 3,447–5,292 | 57% |
| 2030 forecast | – | 4,279 3,428–5,483 | 57% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 27% of the cases CMS names in Indiana; 48 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 48% inpatient hospital, 52% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~4,000 | ~1,900 | ~2,100 |
| 2027 · ~4,100 | ~2,000 | ~2,100 |
| 2028 · ~4,200 | ~2,000 | ~2,100 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 127 | 6,690−0.8%/yr | −0.8%/yr | 5.0 | 4% | 6,500 in 2030−0.5%/yr |
| Ohio | 116 | 5,350−4.9%/yr | −4.9%/yr | 5.0 | 0% | 5,520 in 2030+0.5%/yr |
| Michigan | 80 | 4,354−7%/yr | −7%/yr | 5.4 | 1% | 3,930 in 2030−1.7%/yr |
| Missouri | 69 | 3,704−3.1%/yr | −3.1%/yr | 6.2 | 1% | 3,900 in 2030+0.9%/yr |
| Minnesota | 54 | 2,678−1.9%/yr | −1.9%/yr | 6.2 | 2% | 3,620 in 2030+5.2%/yr |
| Wisconsin | 51 | 2,533−2.6%/yr | −2.6%/yr | 4.7 | 0% | 2,880 in 2030+2.1%/yr |
| Kansas | 48 | 2,322−5%/yr | −5%/yr | 5.9 | 13% | 2,470 in 2030+1%/yr |
| Iowa | 34 | 1,666−1.9%/yr | −1.9%/yr | 3.9 | 0% | 1,710 in 2030+0.5%/yr |
| Nebraska | 20 | 1,389−4%/yr | −4%/yr | 5.5 | 4% | 1,420 in 2030+0.4%/yr |
| South Dakota | 8 | 587−1.6%/yr | −1.6%/yr | 4.7 | 0% | 750 in 2030+4.1%/yr |
| North Dakota | 10 | 559−1.6%/yr | −1.6%/yr | 5.8 | 0% | 640 in 2030+2.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 62 | 3,095+8.8%/yr | +8.8%/yr | 3.71.2× | 0% | 5,760 in 2030+11%/yr |
| LAA occlusion & loop recorders | 68 | 2,697+18%/yr | +18%/yr | 3.31.1× | 0% | 4,650 in 2030+9.5%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Indiana · Every state · Compare with Illinois
Boston Scientific leads with 37% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 9 companies reported engagement with Indiana’s surgeons worth $241K in consulting, speaking, meals and travel tied to these products, about $3,051 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.